Estrogen receptor-negative progesterone receptor-positive breast cancer - "Nobody's land" or just an artifact?

Cancer Treat Rev. 2018 Jun:67:78-87. doi: 10.1016/j.ctrv.2018.05.005. Epub 2018 May 16.

Abstract

The estrogen receptor α (ER) and the progesterone receptor (PgR) are one of the most important prognostic and predictive immunohistochemical markers in breast cancer. Breast cancers may express various profiles of hormone receptors: ER(+)/PgR(+), ER(-)/PgR(-), ER(+)/PgR(-) and ER(-)/PgR(+). The existence of the latter profile is a matter of controversy since PgR expressions is induced by ER-dependent pathways in breast cancer cells. One of the most extensively propagated hypotheses trying to explain the origin of ER(-)/PgR(+) breast cancers claims that they are technical artifacts dependent on the immunohistochemical procedure. On the other hand, in recent years there is a growing body of evidence, suggesting that such cancers create a unique group with distinct molecular and clinical features. In the following review, we present background theories on the ER(-)/PgR(+) breast cancer origin and their epidemiological and clinicopathological characteristics, including the predictive and prognostic significance of these rare tumors.

Keywords: Breast cancer; Estrogen receptor; Pathogenesis; Progesterone receptor; Prognosis.

Publication types

  • Review

MeSH terms

  • Breast Neoplasms / chemistry*
  • Breast Neoplasms / mortality
  • Breast Neoplasms / pathology
  • Female
  • Humans
  • Prognosis
  • Receptors, Estrogen / analysis*
  • Receptors, Progesterone / analysis*

Substances

  • Receptors, Estrogen
  • Receptors, Progesterone